Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and …

EP Baron - Headache: The Journal of Head and Face Pain, 2018 - Wiley Online Library
Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology

A Ligresti, L De Petrocellis… - Physiological …, 2016 - journals.physiology.org
Apart from having been used and misused for at least four millennia for, among others,
recreational and medicinal purposes, the cannabis plant and its most peculiar chemical …

Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

L De Petrocellis, A Ligresti, AS Moriello… - British journal of …, 2011 - Wiley Online Library
BACKGROUND AND PURPOSE Cannabidiol (CBD) and Δ9‐tetrahydrocannabinol (THC)
interact with transient receptor potential (TRP) channels and enzymes of the …

[HTML][HTML] Cannabinoids and epilepsy

EC Rosenberg, RW Tsien, BJ Whalley, O Devinsky - Neurotherapeutics, 2015 - Elsevier
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports,
accumulating animal model data, and mechanistic insights have raised interest in cannabis …

Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis …

EP Baron, P Lucas, J Eades, O Hogue - The journal of headache and pain, 2018 - Springer
Background Medicinal cannabis registries typically report pain as the most common reason
for use. It would be clinically useful to identify patterns of cannabis treatment in migraine and …

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

AC Campos, FA Moreira, FV Gomes… - … of the Royal …, 2012 - royalsocietypublishing.org
Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It
lacks the psychotomimetic and other psychotropic effects that the main plant compound Δ 9 …

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

AA Izzo, F Borrelli, R Capasso, V Di Marzo… - Trends in …, 2009 - cell.com
Δ 9-tetrahydrocannabinol binds cannabinoid (CB 1 and CB 2) receptors, which are activated
by endogenous compounds (endocannabinoids) and are involved in a wide range of …

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

RG Pertwee - British journal of pharmacology, 2008 - Wiley Online Library
Cannabis sativa is the source of a unique set of compounds known collectively as plant
cannabinoids or phytocannabinoids. This review focuses on the manner with which three of …

Molecular and cellular mechanisms of action of cannabidiol

N Martinez Naya, J Kelly, G Corna, M Golino, A Abbate… - Molecules, 2023 - mdpi.com
Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …

From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases

T Cassano, R Villani, L Pace, A Carbone… - Frontiers in …, 2020 - frontiersin.org
Cannabis sativa, commonly known as marijuana, contains a pool of secondary plant
metabolites with therapeutic effects. Besides Δ9-tetrahydrocannabinol that is the principal …